EGFR and non-small cell lung carcinoma: This phase I study was the first-in-human study, conducted to investigate the safety and tolerability, pharmacokinetics (PK), and efficacy of TAS-121 in Japanese patients with advanced EGFR mutation-positive NSCLC who had been previously treated with EGFR-TKIs.